Free Trial
NASDAQ:ALVR

AlloVir Q2 2024 Earnings Report

AlloVir logo
$2.69 +0.01 (+0.37%)
As of 08/1/2025

AlloVir EPS Results

Actual EPS
-$1.15
Consensus EPS
-$2.30
Beat/Miss
Beat by +$1.15
One Year Ago EPS
N/A

AlloVir Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

AlloVir Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

AlloVir's Q2 2025 earnings is scheduled for Thursday, August 7, 2025

Earnings Documents

AlloVir Earnings Headlines

AlloVir (NASDAQ:ALVR) Shares Down 2.8% - Here's What Happened
Kalaris Announces Closing of Merger with AlloVir
Market Crash Warning: How to Protect Your Wealth Before August 12th
New China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shifting out of stocks, while everyday investors remain exposed. A free guide reveals where the smart money is going—and how to protect your wealth before the next sell-off.
Kalaris, AlloVir announce stockholder approval of merger
See More AlloVir Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AlloVir? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AlloVir and other key companies, straight to your email.

About AlloVir

AlloVir (NASDAQ:ALVR) engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

View AlloVir Profile

More Earnings Resources from MarketBeat